Updated May 2026 · ClinicalTrials.gov
National Institutes of Health Clinical Center (CC)
4 clinical trials · 4 recruiting · NIH
National Institutes of Health Clinical Center (CC) has 4 clinical trials registered on ClinicalTrials.gov, with 4 actively recruiting participants. The trials listed below cover 9 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.
About National Institutes of Health Clinical Center (CC)\'s Trial Portfolio
National Institutes of Health Clinical Center (CC) is a federal-government sponsor. Government-funded trials, including those from the National Institutes of Health, are typically focused on public-health priorities, rare-disease research, and questions where commercial sponsors have less incentive to fund. They are also among the most rigorously documented trials on ClinicalTrials.gov.
4 of National Institutes of Health Clinical Center (CC)'s 4 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.
National Institutes of Health Clinical Center (CC)'s research footprint spans Pulmonary Arterial Hypertension (1 trials), Pulmonary Disease (1), and Pulmonary Hypertension (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.
is the largest single phase in National Institutes of Health Clinical Center (CC)'s portfolio at 50% of registered trials. The full phase breakdown appears in the sidebar.
Trials by National Institutes of Health Clinical Center (CC)
Spironolactone for Pulmonary Arterial Hypertension
Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate...
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH...
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement...
Background: People with cerebral palsy, spina bifida, muscular dystrophy, or spinal cord injury often have muscle weakness and problems controlling how their legs move. This can...
Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed...
How to Approach a Trial Listing
Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.
Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.
Authoritative Resources
Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.
Frequently Asked Questions
How many clinical trials does National Institutes of Health Clinical Center (CC) have on ClinicalTrials.gov?
National Institutes of Health Clinical Center (CC) has 4 clinical trials registered on the federal ClinicalTrials.gov registry, of which 4 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.
What conditions does National Institutes of Health Clinical Center (CC) study?
National Institutes of Health Clinical Center (CC)'s registered trials cover 9 conditions on ClinicalTrials.gov, led by Pulmonary Arterial Hypertension (1 trial), Pulmonary Disease (1 trial), Pulmonary Hypertension (1 trial), Cerebral Palsy (1 trial), Muscular Dystrophy (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.
How do I join a National Institutes of Health Clinical Center (CC) clinical trial?
Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.
What does the trial phase mean?
Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.
Where does this trial data come from?
All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.
How This Sponsor Page Is Built
Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.
Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."
Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
Last updated 2026-05-08 · 4 trials tracked for National Institutes of Health Clinical Center (CC).
this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.
The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.